Samuel L Aitken (Samuel Aitken, S Aitken)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Venues

JAC-antimicrobial resistance

mBio

Antimicrobial agents and chemotherapy

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

University of Texas MD Anderson Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas MD Anderson Cancer Center Aug 01 2014

United States

Clinical Pharmacy Specialist - Infectious Diseases :: Division of Pharmacy

Publications

Akito Kawai, William C Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Micah M Bhatti, Ryan K Shields, Samuel A Shelburne Iii, Yohei Doi
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio 15 (2) (2024)
Akito Kawai, William C Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Micah M Bhatti, Ryan K Shields, Samuel A Shelburne Iii, Yohei Doi
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio 15 (2) (2024)
Akito Kawai, William C Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Micah M Bhatti, Ryan K Shields, Samuel A Shelburne Iii, Yohei Doi
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio 15 (2) (2024)
Samuel L Aitken, Virginia M Pierce, Jason M Pogue, Ellen G Kline, Frank P Tverdek, Ryan K Shields
The growing threat of NDM-producing E. coli with penicillin-binding protein 3 mutations in the United States - is there a potential role for durlobactam? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Akito Kawai, William C Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Micah M Bhatti, Ryan K Shields, Samuel A Shelburne Iii, Yohei Doi
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio (2024)
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne Iii, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC-antimicrobial resistance 5 (1) (2023)
William C Shropshire, Bradley T Endres, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Chin-Ting Wu, Stephanie L Egge, Ayesha Khan, William R Miller, Micah M Bhatti, Pranoti Saharasbhojane, Akito Kawai, Ryan K Shields, Samuel A Shelburne Iii, Yohei Doi
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant. The Journal of antimicrobial chemotherapy (2023)
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne Iii, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC-antimicrobial resistance 5 (1) (2023)
William C Shropshire, Hatim Amiji, Jordan Bremer, Selvalakshmi Selvaraj Anand, Benjamin Strope, Pranoti Sahasrabhojane, Marc Gohel, Samuel L Aitken, Sarah Spitznogle, Xiaowei Zhan, Jiwoong Kim, David E Greenberg, Samuel A Shelburne Iii
Genetic determinants underlying the progressive phenotype of β-lactam/β-lactamase inhibitor resistance in Escherichia coli . Microbiology spectrum (2023)
Elaine Liu, Andrea M Prinzi, Jovan Borjan, Samuel L Aitken, Patricia A Bradford, William F Wright
#AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance. JAC-antimicrobial resistance 5 (4) (2023)
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne Iii, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC-antimicrobial resistance 5 (1) (2023)
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne Iii, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC-antimicrobial resistance 5 (1) (2023)
Truc T Tran, Sara Gomez Villegas, Samuel L Aitken, Susan M Butler-Wu, Alex Soriano, Brian J Werth, Jose M Munita
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides. Antimicrobial agents and chemotherapy 66 (6) (2022)
William C Shropshire, Anna Konovalova, P McDaneld, M Gohel, B Strope, P Sahasrabhojane, C N Tran, David E Greenberg, J Kim, X Zhan, Samuel L Aitken, Micah M Bhatti, T C Savidge, Todd J Treangen, Blake M Hanson, César A Arias, Samuel A Shelburne Iii
Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant Enterobacterales Bloodstream Infections. mSystems 7 (5) (2022)
Eduardo A Yepez Guevara, Samuel L Aitken, Adilene V Olvera, Lily Carlin, Kerri E Fernandes, Micah M Bhatti, Kevin W Garey, Javier Adachi, Pablo C Okhuysen
Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 72 (10) (2021)
Emily L Heil, Samuel L Aitken, David E Nix, Richard Drew, Warren E Rose, Susan L Davis, Julie Ann Justo, Douglas N Fish, Jason M Pogue, null null
Recommended Revisions to the National SEP-1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. Pharmacotherapy 40 (4) (2021)
Joseph Sassine, Fareed Khawaja, Terri Lynn Shigle, Victoria Handy, Farnaz Foolad, Samuel L Aitken, Ying Jiang, Richard Champlin, Elizabeth Shpall, Katy Rezvani, Ella J Ariza-Heredia, Roy F Chemaly
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 73 (8) (2021)
Samuel L Aitken, Pranoti V Sahasrabhojane, Dimitrios P Kontoyiannis, Tor C Savidge, Cesar A Arias, Nadim J Ajami, Samuel A Shelburne, Jessica R Galloway-Peña
Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 72 (9) (2021)
Kenneth V I Rolston, Baghat Gerges, Samuel Shelburne, Samuel L Aitken, Issam Raad, Randall A Prince
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Antimicrobial agents and chemotherapy 64 (5) (2020)
Hannah K Spencer, Sarah L Spitznogle, Jovan Borjan, Samuel L Aitken
An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria. Pharmacotherapy 40 (9) (2020)
Nicolo L Cabrera, Alexandre E Malek, Samuel L Aitken, Cesar A Arias
Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis: Caution in Interpreting the Results. Antimicrobial agents and chemotherapy 64 (4) (2020)
Grace E Benanti, Anne Rain T Brown, Terri Lynn Shigle, Jeffrey J Tarrand, Micah M Bhatti, Patrick M McDaneld, Samuel A Shelburne, Samuel L Aitken
Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy. Antimicrobial agents and chemotherapy 63 (2) (2019)
Stephanie A Folan, Kayleigh R Marx, Frank P Tverdek, Issam Raad, Victor E Mulanovich, Jeffrey J Tarrand, Samuel A Shelburne, Samuel L Aitken
Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia. Open forum infectious diseases 5 (7) (2018)

Samuel L Aitken.css-eqlu8i{font-size:small;padding-left:4px;} (Samuel Aitken, S Aitken)

Publication Activity (10 Years)

Top Topics

Top Venues

Samuel L Aitken (Samuel Aitken, S Aitken)